On October 5, 2023 XNK Therapeutics AB reported that Anna-Karin Maltais, Chief Scientific Officer, will be speaking at the 2nd Annual Innate Killer Europe Summit in London on October 18 (Press release, XNK Therapeutics, OCT 5, 2023, View Source [SID1234635701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The meeting is the second Innate Killer Europe Summit following last year’s first European version of the larger annual US Innate Killer Summit. The purpose of the meeting is to build community and collaboration to leverage innovative European R&D and transform the innate immune space. The summit gathers 80+ key European natural killer, natural killer T, neutrophil, gamma delta T and macrophage thought leaders to discuss how innate immunotherapies, through effective and scalable engineering, cell engager and combined modality strategies, can help bring safe, potent, and persistent innate immune therapies to patients in need.

On October 18, 2023, Dr. Maltais will present XNK and discuss how to harness autologous NK cells for personalized immunotherapy. She will discuss engineering vs non-engineering strategies, important aspects of repeat dosing as well as strategies to increase cell potency, targeting and persistence.